Spermatogenesis Preservation
MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis under mechanical stress.
[1]MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial DNA, specifically the 12S ribosomal RNA gene. It is one of a small class of mitochondrially-derived peptides that function as retrograde signaling molecules from mitochondria to the nucleus. MOTS-c is a hormone-like regulator of metabolic homeostasis, exercise capacity, and insulin sensitivity, with rapidly growing literature in the longevity and metabolic space.
At a glance
- Type
- 16-amino-acid peptide encoded within mitochondrial DNA (12S ribosomal RNA gene)
- Class
- Mitochondrially-derived peptide; retrograde signaling molecule from mitochondria to the nucleus
- Mechanism
- AMPK activation supporting fatty acid oxidation, glucose uptake, and mitochondrial biogenesis
- Route
- Subcutaneous
- Stacking
- SS-31 (Elamipretide) and NAD+ precursors
- WADA
- Banned for competitive athletes
What the research supports
MOTS-c's evidence base centers on AMPK activation, exercise mimetic activity, and emerging cardiovascular and reproductive applications.
Vascular Stiffness and Oxidative Stress
Pilot work in peritoneal dialysis patients shows MOTS-c levels correlate with arterial stiffness and oxidative stress markers, suggesting a mitochondrial-vascular axis.
[2]Musculoskeletal Peptide Safety Review
Reviewed alongside other recovery and exercise mimetic peptides for safety and efficacy in musculoskeletal applications.
[3]AMPK and Mitochondrial Biogenesis
Activates AMPK and downstream metabolic pathways supporting fatty acid oxidation, glucose uptake, and mitochondrial biogenesis.
Summary of key findings
Mitochondrially Encoded Peptide
Unique among regenerative peptides; endogenously produced from mitochondrial DNA as a retrograde signal to the nucleus.
Exercise Mimetic Activity
Improves exercise capacity in animal models without training stimulus; a complement to training, not a substitute.
Endogenous Decline with Age
Levels parallel the decline in mitochondrial function and metabolic flexibility seen clinically with aging.
Pairs with SS-31 and NAD+
Mitochondrial-focused stacking with SS-31 (Elamipretide) and NAD+ precursors covers complementary mechanisms.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- Subcutaneous Protocol (standard)
- 5 to 10 mg subcutaneous, 1 injection every 5 days for 20 days. AM empty stomach.
- Maintenance Pattern
- 1 mg every other day to support lower blood sugars in T2D contexts.
- Type 2 Diabetes
- 10 mg 1x weekly for 8 weeks; 3x annually. Multiple follow-up protocols available.
- Cycling Notes
- Lower dose 5 mg requires 2 bottles per cycle; higher dose 10 mg requires 4 bottles per cycle.
Vial reference
Units are for a U-100 insulin syringe (100 units = 1 mL), computed from the vial concentration.
| Vial | Dose range | Units per dose | Frequency | Notes |
|---|---|---|---|---|
| MOTS-c 10 mg / 1 mL | 5 to 10 mg | 50 to 100 units | 1 injection every 5 days for 20 days | 0.1 mg per unit. AM empty stomach. 3x annually. |
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
MOTS-c is unique among regenerative peptides because it is endogenously encoded by mitochondrial DNA. Endogenous levels decline with age, paralleling the decline in mitochondrial function and metabolic flexibility seen clinically. Position it as a mitochondrial support peptide for patients with metabolic syndrome, insulin resistance, or significant fatigue.
The exercise mimetic angle is real but should not replace exercise; frame as a complement to training. Recent 2026 work expanded the application space significantly: spermatogenesis preservation under stress, vascular biology in dialysis patients. Pairs well with SS-31 for mitochondrial-focused protocols, and with NAD+ precursors for broader energy metabolism support. Banned by WADA.
Metabolic Homeostasis
AMPK activation, fatty acid oxidation, insulin sensitivity improvement.
Exercise Mimetic
Improves capacity in animal models; complement to training.
Mitochondrial Aging
Endogenous levels decline with age; restoration supports cellular bioenergetics.
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Liu et al., 2026, Free Radical Biology and Medicine MOTS-c Preserves Spermatogenesis via SLC7A11 Ferroptosis Suppression
- 2Musolino et al., 2026, International Urology and Nephrology MOTS-c and Arterial Stiffness in Peritoneal Dialysis
- 3Mendias and Awan, 2026, Sports Medicine Peptide Therapies for Musculoskeletal Injuries Safety Review
- 4MOTS-c Retrograde Signaling Mechanism ReviewCitation under review
Regulatory status, cautions and contraindications
Pregnancy and Lactation
Insufficient data; avoid use during pregnancy and lactation until further evidence is available.
Active Malignancy
Mixed theoretical considerations; coordinate with oncology before initiating any peptide protocol.
Hypoglycemia Risk
Monitor glucose closely in patients on insulin or sulfonylureas due to potential additive hypoglycemic effects.
WADA Prohibition
MOTS-c is banned by WADA for competitive athletes. Not for use in sanctioned sport.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.